HK1206721A1 - 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- - Google Patents
2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23--Info
- Publication number
- HK1206721A1 HK1206721A1 HK15107160.2A HK15107160A HK1206721A1 HK 1206721 A1 HK1206721 A1 HK 1206721A1 HK 15107160 A HK15107160 A HK 15107160A HK 1206721 A1 HK1206721 A1 HK 1206721A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cns
- indoles
- dihydro
- oxo
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12184249 | 2012-09-13 | ||
PCT/EP2013/068668 WO2014040969A1 (en) | 2012-09-13 | 2013-09-10 | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206721A1 true HK1206721A1 (en) | 2016-01-15 |
Family
ID=47044777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107160.2A HK1206721A1 (en) | 2012-09-13 | 2015-07-27 | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- |
Country Status (23)
Country | Link |
---|---|
US (1) | US9221816B2 (es) |
EP (1) | EP2895476B1 (es) |
JP (1) | JP6116693B2 (es) |
KR (1) | KR101706877B1 (es) |
CN (1) | CN104619701B (es) |
AR (1) | AR092555A1 (es) |
AU (1) | AU2013314417B2 (es) |
BR (1) | BR112015005186A2 (es) |
CA (1) | CA2883817C (es) |
CL (1) | CL2015000559A1 (es) |
CR (1) | CR20150084A (es) |
EA (1) | EA027176B1 (es) |
ES (1) | ES2590531T3 (es) |
HK (1) | HK1206721A1 (es) |
IL (1) | IL237266A0 (es) |
MA (1) | MA37943B1 (es) |
MX (1) | MX2015003330A (es) |
PE (1) | PE20150943A1 (es) |
PH (1) | PH12015500400A1 (es) |
SG (1) | SG11201501923WA (es) |
TW (1) | TWI490213B (es) |
WO (1) | WO2014040969A1 (es) |
ZA (1) | ZA201501262B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX370661B (es) * | 2013-06-19 | 2019-12-19 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. |
JP6445588B2 (ja) * | 2014-05-22 | 2018-12-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インドリン−2−オン及び1,3−ジヒドロ−ピロロ[3,2−c]ピリジン−2−オン誘導体 |
CR20160578A (es) * | 2014-06-26 | 2017-02-21 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin-2-ona |
PT3371168T (pt) | 2015-11-06 | 2020-07-17 | H Hoffnabb La Roche Ag | Derivados de indolin-2-ona |
EP3371169B1 (en) | 2015-11-06 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
CN108137555B (zh) | 2015-11-06 | 2021-02-19 | 豪夫迈·罗氏有限公司 | 可用于治疗cns疾病的二氢吲哚-2-酮衍生物 |
EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
CN106065008B (zh) * | 2016-06-16 | 2018-06-05 | 黑龙江中医药大学 | 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用 |
GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
WO2023250064A1 (en) * | 2022-06-23 | 2023-12-28 | Biogen Ma Inc. | Tyrosine kinase 2 inhibitors and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR851085B (es) | 1984-05-12 | 1985-11-25 | Boehringer Mannheim Gmbh | |
DE3417643A1 (de) | 1984-05-12 | 1985-11-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
DE3445669A1 (de) | 1984-12-14 | 1986-06-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4835280A (en) | 1985-01-18 | 1989-05-30 | Boehringer Mannheim Gmbh | Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles |
DE3501497A1 (de) | 1985-01-18 | 1986-07-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte |
DE3803775A1 (de) | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
DE3818830A1 (de) | 1988-06-03 | 1989-12-14 | Boehringer Mannheim Gmbh | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel |
DE3925584A1 (de) | 1989-08-02 | 1991-02-07 | Boehringer Mannheim Gmbh | Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
CA2383623A1 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
CA2368041A1 (en) | 1999-03-24 | 2000-09-28 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
CN100562513C (zh) * | 2003-06-12 | 2009-11-25 | 安斯泰来制药有限公司 | 苯甲酰胺衍生物或其盐 |
AU2004247559B2 (en) * | 2003-06-12 | 2009-08-27 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
ZA200703912B (en) | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
US20060142247A1 (en) | 2004-12-17 | 2006-06-29 | Guy Georges | Tricyclic heterocycles |
AU2006319916A1 (en) * | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
AU2008281877A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of CNS disorders |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
EP2638014B1 (en) * | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
-
2013
- 2013-09-10 AU AU2013314417A patent/AU2013314417B2/en not_active Ceased
- 2013-09-10 KR KR1020157009290A patent/KR101706877B1/ko active IP Right Grant
- 2013-09-10 EA EA201590438A patent/EA027176B1/ru not_active IP Right Cessation
- 2013-09-10 EP EP13759241.6A patent/EP2895476B1/en active Active
- 2013-09-10 BR BR112015005186A patent/BR112015005186A2/pt not_active IP Right Cessation
- 2013-09-10 SG SG11201501923WA patent/SG11201501923WA/en unknown
- 2013-09-10 MX MX2015003330A patent/MX2015003330A/es unknown
- 2013-09-10 CA CA2883817A patent/CA2883817C/en not_active Expired - Fee Related
- 2013-09-10 WO PCT/EP2013/068668 patent/WO2014040969A1/en active Application Filing
- 2013-09-10 ES ES13759241.6T patent/ES2590531T3/es active Active
- 2013-09-10 CN CN201380047631.2A patent/CN104619701B/zh active Active
- 2013-09-10 JP JP2015531533A patent/JP6116693B2/ja active Active
- 2013-09-10 PE PE2015000365A patent/PE20150943A1/es not_active Application Discontinuation
- 2013-09-12 TW TW102133020A patent/TWI490213B/zh not_active IP Right Cessation
- 2013-09-13 AR ARP130103279A patent/AR092555A1/es unknown
-
2015
- 2015-02-16 IL IL237266A patent/IL237266A0/en unknown
- 2015-02-19 CR CR20150084A patent/CR20150084A/es unknown
- 2015-02-24 ZA ZA2015/01262A patent/ZA201501262B/en unknown
- 2015-02-24 PH PH12015500400A patent/PH12015500400A1/en unknown
- 2015-03-06 CL CL2015000559A patent/CL2015000559A1/es unknown
- 2015-03-11 US US14/645,033 patent/US9221816B2/en active Active
- 2015-03-20 MA MA37943A patent/MA37943B1/fr unknown
- 2015-07-27 HK HK15107160.2A patent/HK1206721A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015500400A1 (en) | 2015-04-27 |
MA37943B1 (fr) | 2016-11-30 |
KR101706877B1 (ko) | 2017-02-15 |
ZA201501262B (en) | 2016-03-30 |
BR112015005186A2 (pt) | 2017-07-04 |
JP2015529673A (ja) | 2015-10-08 |
CN104619701A (zh) | 2015-05-13 |
CN104619701B (zh) | 2016-10-19 |
MA37943A1 (fr) | 2016-04-29 |
PE20150943A1 (es) | 2015-06-20 |
CA2883817A1 (en) | 2014-03-20 |
EA201590438A1 (ru) | 2015-06-30 |
TW201416358A (zh) | 2014-05-01 |
WO2014040969A1 (en) | 2014-03-20 |
TWI490213B (zh) | 2015-07-01 |
AU2013314417A1 (en) | 2015-03-05 |
CL2015000559A1 (es) | 2015-07-10 |
KR20150054991A (ko) | 2015-05-20 |
EA027176B1 (ru) | 2017-06-30 |
CR20150084A (es) | 2015-04-06 |
CA2883817C (en) | 2017-09-05 |
ES2590531T3 (es) | 2016-11-22 |
AU2013314417B2 (en) | 2016-01-21 |
IL237266A0 (en) | 2015-04-30 |
US9221816B2 (en) | 2015-12-29 |
MX2015003330A (es) | 2015-06-05 |
EP2895476B1 (en) | 2016-06-22 |
AR092555A1 (es) | 2015-04-22 |
SG11201501923WA (en) | 2015-04-29 |
JP6116693B2 (ja) | 2017-04-19 |
US20150284386A1 (en) | 2015-10-08 |
EP2895476A1 (en) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL237275A0 (en) | Compounds for the treatment of paramoxovirus viral infections | |
HK1206721A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- | |
GB2503852B (en) | Compounds for the treatment of neuropsychiatric disorders | |
EP2812298A4 (en) | IMPROVED PROCESS FOR PRODUCING 2,3,3,3-TETRAFLUOROPROPENE | |
HK1213544A1 (zh) | 新型二環苯基-吡啶/吡嗪用於治療癌症 | |
HRP20181481T1 (hr) | D-metadon za liječenje psihijatrijskih simptoma | |
HRP20190038T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
HK1210225A1 (en) | Procedure for the production of tiacumicin | |
HK1204603A1 (zh) | 用於治療中樞神經系統疾病的苄胺的磺酰胺衍生物 | |
EP2934565A4 (en) | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC ILLNESSES | |
IL237912B (en) | History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders | |
IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
EP2970118A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
GB201207363D0 (en) | Compounds for the treatment of metabolic disorders |